Home > Boards > US Listed > Medical - Drugs >

Abeona Therapeutics (ABEO)

Add ABEO Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 10/25/2018 9:13:17 AM - Followers: 50 - Board type: Free - Posts Today: 0


Web Site: http://abeonatherapeutics.com/


Abeona Therapeutics Announces Fourth Quarter and Full Year 2015 Summary Financial Results and Recent Operational Highlights

NEW YORK, NY and CLEVELAND, OH -- (Marketwired) -- 03/08/16 --  Abeona Therapeutics, Inc. (NASDAQ: ABEO), a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, today announced summary financial results for the fourth quarter and full fiscal year ended December 31, 2015. The Company will provide a business update for investors and other stakeholders on a conference call, Wednesday, March 9th, at 4:45 pm (Eastern). Tim Miller, Ph.D., President and CEO and Jeffrey Davis, Chief Operating Officer, together with other executives, will conduct the call. Interested parties are invited to participate in the call by dialing 877-269-7756 (toll free domestic) or 201-689-7817 (international). The call will consist of an overview of the Company's 4Q15 financials, and a discussion of business highlights.

"The past year has led to significant advancements in our goal of building a leadership position in the field of gene therapy and plasma protein therapies towards transforming the lives of patients with rare diseases," stated Steven H. Rouhandeh, Executive Chairman. "In 2015, we expanded our pipeline with two clinical stage AAV gene therapies for Sanfilippo syndrome types A and B, added a third AAV gene therapy product in Juvenile Neuronal Ceroid Lipofuscinosis (JNCL) (also known as juvenile Batten disease), signed a license to an innovative CRISPR-Cas9 gene editing platform in rare blood disorders, with an initial focus in Fanconi anemia, strengthened our team, and added substantial financial resources to our balance sheet. In 2016, our priorities include driving our AAV gene therapy and alpha-1 protease inhibitor programs into the clinic, and advancing our gene editing programs including defining of regulatory pathways to bring our CRISPR product candidates to patients."

Tim Miller, Ph.D., President and CEO, stated, "2016 will be an exciting, transformative year for Abeona Therapeutics as we position ourselves to enter multiple human clinical trials with our pipeline of innovative product candidates. As recently announced, the FDA allowance of the IND for the Phase 1/2 clinical study of ABO-102 for patients with Sanfilippo syndrome type A (MPS IIIA) moves our programs into the clinic here in the US, and we look forward to working with our collaborators to expand this program into Europe and Australia later this year. We believe that our gene therapy programs in Sanfilippo syndrome type B (ABO-101) and Juvenile Neuronal Ceroid Lipofuscinosis (ABO-201) will follow shortly. Lastly, we would like to thank our dedicated researchers and clinical collaborators, as well as the many dedicated patient foundations, for their tireless efforts and commitment to advancing new treatment options for these devastating unmet medical needs."

Recent Abeona Highlights

  • Sanfilippo syndrome gene therapy programs: On February 29, 2016, Abeona announced the FDA allowance of an Investigational New Drug (IND) for systemic AAV Phase 1/2 clinical study with ABO-102 gene therapy for patients with Sanfilippo syndrome type A (MPS IIIA). On January 11, 2016, we announced that initial regulatory approvals from European bodies -- the Genetically Modified Organism (GMO) Voluntary Release regulatory filings, and the ethical committee regulatory filings -- for both the ABO-101 and ABO-102 programs in Spain. Abeona plans to commence both programs for the upcoming human clinical trials to be conducted at Cruces University Hospital in Bilbao, Spain. Both the ABO-101 and ABO-102 programs have received Orphan Drug and Pediatric Rare Disease designations from the FDA.
    SDF-Alpha plasma protein program: Abeona has completed optimization of the downstream chromatography steps for our SDF-Alpha™ (alpha-1 protease inhibitor) for inherited COPD. Additional provisional patent applications have been filed to provide the Company with expanded intellectual property protection. The Company has expanded its CMO relationships to ensure it has the ability to manufacture clinical material for future trials. The Company confirms that its proprietary SDF platform provides significantly enhanced yields of alpha-1 protease inhibitor, at levels up to 10 times of that achievable with the industry standard Cohn processes, and with purity levels consistent with that achieved by other commercial processes.
    Advanced pipeline programs: Together with its academic collaborators, the Company continued to progress its pre-clinical programs in juvenile Batten disease and its CRISPR-Cas9 program in Fanconi anemia (FA) and other rare blood disorders. Juvenile Batten disease is the most common form of a group of disorders known as neuronal ceriod lipofuscinosis (NCL), a lysosomal storage disease that affects the nervous system in children and for which there are no approved treatment options. Fanconi anemia is a rare pediatric blood disease characterized by multiple physical abnormalities, bone marrow failure and a higher than normal risk of cancer. 
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ABEO News: Statement of Changes in Beneficial Ownership (4) 05/23/2019 06:30:06 PM
ABEO News: Statement of Changes in Beneficial Ownership (4) 05/23/2019 06:28:25 PM
ABEO News: Statement of Changes in Beneficial Ownership (4) 05/23/2019 06:26:44 PM
ABEO News: Statement of Changes in Beneficial Ownership (4) 05/23/2019 06:24:48 PM
ABEO News: Statement of Changes in Beneficial Ownership (4) 05/22/2019 05:11:26 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#1169   They missed their target big time, but I hedge_fun 10/25/18 09:13:17 AM
#1168   Chart is ?? ting up Kylef 10/07/18 05:33:34 PM
#1167   YAA me TOO. Moved on to a good NotRichYet2 02/16/18 08:24:31 PM
#1166   ABEO buy 15.80 stocktrademan 12/04/17 12:03:06 PM
#1165   This company is getting a lot of media airsplash2000 11/10/17 04:49:06 PM
#1164   Nice run more to come IMO Roofer73 10/20/17 12:53:33 PM
#1163   5 million shares @ $16 plus grants plus Roofer73 10/17/17 06:47:54 AM
#1162   It was trading like a secondary and only Roofer73 10/16/17 04:14:08 PM
#1161   Canter Fitzgerald raises target price up to $34.00. Bute 10/12/17 10:45:26 AM
#1160   Good news and move up! Roofer73 10/11/17 09:36:02 AM
#1159   CitiGroup gives ABEO a buy rating and a Bute 10/10/17 09:57:42 AM
#1158   Viking Global adds 2,238,720 shares in SC13g filing 10/2/17 Roofer73 10/10/17 06:58:35 AM
#1157   Headed for $24 plus IMO Roofer73 09/28/17 02:32:21 PM
#1156   Analyst upgrades today. Read PR on your brokerage account. crudeoil24 09/15/17 11:16:07 AM
#1155   Nice $24 price target from RBC Capital Roofer73 09/15/17 10:08:23 AM
#1154   another big pop over $17. Can't find Bobwins 09/15/17 09:59:20 AM
#1153   https://seekingalpha.com/article/4103962-3-things-biotech-learn-today-september- Avispa 09/05/17 08:04:38 AM
#1152   Exceeding all my expectations! More to come IMO Roofer73 08/30/17 09:37:09 PM
#1151   Way too many little milestones lined up over seventhwave 08/30/17 03:29:05 PM
#1150   rally was based on news that FDA granted Bobwins 08/30/17 09:34:51 AM
#1149   Lord why didn't I buy back 2 months ago? hedge_fun 08/30/17 07:48:47 AM
#1148   BTD baby!!! This board needs to seriously wake up! seventhwave 08/29/17 09:17:02 PM
#1147   Abeona Therapeutics Receives Guidance from FDA to Commence nlightn 07/18/17 08:50:10 AM
#1146   Abeona: Preparing For Liftoff - The Next AveXis? nlightn 06/29/17 08:48:08 AM
#1145   Rare Diseases: Biotech's High Risk, Highest Reward Sub-Sector nlightn 06/29/17 08:38:19 AM
#1144   Abeona Therapeutics Receives FDA Orphan Drug Designation for nlightn 06/29/17 08:27:21 AM
#1143   Abeo closes offering @ $7.00 Roofer73 11/01/16 04:08:46 PM
#1142   6 million shares @ $7.00 is the offering Roofer73 10/27/16 09:20:57 AM
#1141   Isn't size and price of an offering a Roofer73 10/26/16 05:13:59 PM
#1140   no i'm sitting with free shares...i'm good Bob Stocks 10/20/16 08:44:39 PM
#1139   Oops! Glider549 10/18/16 12:38:00 PM
#1138   ABEO bullish 6.86 stocktrademan 10/10/16 05:00:49 PM
#1137   ABEO bullish 6.8223 stocktrademan 10/07/16 11:58:52 AM
#1136   I wouldnt say "no posts" ;) longhorn4lif 10/01/16 11:23:46 AM
#1135   I sold half also Bob Stocks 09/23/16 06:07:37 PM
#1134   Just sold half my position, sort of as hedge_fun 09/20/16 02:38:43 PM
#1133   NICE Bob Stocks 09/20/16 12:27:49 PM
#1132   She doesn't act as if she wants to hedge_fun 09/20/16 09:56:19 AM
#1131   Check out the article SeekingAlpha put out today 9/16/2016 Glider549 09/16/16 03:14:58 PM
#1130   Doubled since July...and no posts Bob Stocks 09/15/16 09:59:04 PM
#1129   $5 AH. Very nice..... hedge_fun 09/07/16 05:05:48 PM
#1128   Great long term play here but 4.30 is longhorn4lif 08/19/16 12:11:59 PM
#1127   Still pretty low volume....seems under radar still to me! longhorn4lif 08/17/16 07:36:07 PM
#1126   It's noticed. It's just not being commented on...... hedge_fun 08/17/16 09:34:33 AM
#1125   $4 today stil nobody notices wow longhorn4lif 08/16/16 10:40:58 PM
#1124   took a little longer then I thought to longhorn4lif 08/04/16 07:05:09 PM
#1123   still nobody like this play. Another long longhorn4lif 08/04/16 07:04:03 PM
#1122   Nobody found you yet? Dont worry your longhorn4lif 06/01/16 05:25:29 PM
#1121   ready now longhorn4lif 04/23/16 12:29:19 AM
#1120   Lonely and forgotten for now.....dont worry nobody wants longhorn4lif 04/14/16 10:14:50 AM